SymBio Pharmaceuticals Limited
Unsecured Bond Facility Agreement and Issuance of the Second Unsecured Ordinary Bond (Private Placement) and Third-Party Allotment of the 70th and 71st Warrants and Conclusion of the Buyback Agreement
Setting up a unsecured bond facility of up to 5 billion yen with EVO FUND as the, issuer; issuing the Second Unsecured Ordinary Bond. Warrants for the 70th and 71st will be allocated to EVO FUND, with a revised exercise price linked to stock price. Funds will be mainly used for the development costs of Brincidovir and future clinical trial expenses. Designing a roughly 3-year funding plan with an eye toward new drug approval applications in 2028. Currently, additional measures may be taken depending on funding progress and stock price movement.
Key Figures
- 6,768,880,000円: 調達資金額（総額）
- 96,000,000株: 第70回新株予約権・第71回新株予約権の全付与後の潜在株式数
- 4円/2円: 第70回新株予約権・第71回新株予約権の払込価額
- 3年間: 資金調達期間
- EU・US・UKを含む臨床開発計画の対象
AI要約
Overview of fundraising
SinBio Pharmaceuticals adopts a fundraising scheme combining new warrant-attached bonds with an allocation to EVO FUND. The facility agreement allows unsecured bonds up to 5 billion yen, with the issuance of the Second Unsecured Ordinary Bond planned. The 70th and 71st warrants are allocated to EVO FUND, with an adjusted exercise price linked to the stock price. The funds will be primarily allocated to development costs for Brincidovir and future clinical trial expenses.
Outlook and risks
Funding is part of a routine to support a roughly three-year development plan and to secure ongoing clinical trials toward a 2028 new drug approval. On the other hand, the actual amount of financing may vary depending on stock price movements, raising risks of share dilution and market impact. The third-party allotment is expected to cause dilution of over 25%, with input from a third-party committee.
SinBio Pharmaceuticals, Ltd.
Company overview · Stock price · Financial data · All IR
